Carpal tunnel syndrome and type of dialysis membrane used in patients undergoing long‐term hemodialysis

Chanard, J; Lavaud, Sylvie; Toupance, Olivier; Roujouleh, Haycam; Melin, Jean-Pierre

doi:10.1002/art.1780290919

Cited by 21 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hemodialysis using AN 69 membranes may prevent, or at least postpone the develop ment of dialysis amyloidosis. These findings also confirm the earlier observations of Chanard et al [3,5] and van Ypersele de Strihou et al [4] that dialysis amyloidosis is less common in patients treated with AN 69 membranes than in those dialyzed with standard cuprophane membranes.…”

Section: Discussionsupporting

confidence: 82%

“…Some clinical studies have indicated that the prevalence of dialysis amyloidosis may depend on the dialy sis membrane used. In these studies, the prevalence of amyl oidosis has been found to be higher in patients dialyzed with standard cuprophane membranes than in those treated with the more biocompatible polyacrylonitrile AN 69 membranes [3][4][5][6], Other investigators have not been able to confirm these findings, however [7,8],…”

Section: Introductionmentioning

confidence: 50%

See 1 more Smart Citation

Radiolucent Bone Cysts and the Type of Dialysis Membrane Used in Patients Undergoing Long-Term Hemodialysis

Miura¹,

Ishiyama²,

Inomata³

et al. 1992

Nephron

View full text Add to dashboard Cite

The relationship between the types of dialysis membrane used and the prevalence and severity of radiolucent bone cysts (which are a main radiological feature of dialysis amyloidosis) was studied in 30 patients on hemodialysis for more than 10 years. One of them was treated exclusively with cuprophane; the other 29 were dialyzed with cuprophane, and then treated with polyacrylonitrile AN 69. In 12 of the 30 patients, radiolucent bone cysts (at least 5 mm in diameter in the wrists and at least 10 mm in the shoulders or hips) were observed. The patients with bone cysts spent significantly more time on cuprophane dialysis and significantly less time on AN 69 dialysis than the group of patients without bone cysts. Nine of the 14 patients who had been treated with cuprophane for more than 8 years had bone cysts; whereas bone cysts were observed in only 2 of the 12 patients dialyzed for more than 8 years with AN 69. The frequency of bone cysts was significantly different for each of the two groups. There was, however, no significant difference in the total duration of dialysis between the two groups. The severity of the cystic bone lesions correlated positively with the duration of dialysis using cuprophane and negatively with the duration of dialysis using AN 69. These findings suggest that the development of osteoarticular amyloidosis may be related to the type of dialysis membrane used. Hemodialysis using AN 69 membranes may prevent, or at least postpone the development of dialysis amyloidosis.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 50%

Radiolucent Bone Cysts and the Type of Dialysis Membrane Used in Patients Undergoing Long-Term Hemodialysis

Miura¹,

Ishiyama²,

Inomata³

et al. 1992

Nephron

View full text Add to dashboard Cite

show abstract

“…Common findings usually comprise calcific periarthritis [4], recurrent acute (gouty?) arthritic episodes [5], carpal tunnel syndrome [6], synovial amyloidosis, renal osteodystrophy, dialysis arthropathy and secondary hyperparathyroidism [7,8]. The additional occurrence of destructive spondylarthropathy in haemodialized patients has been discussed in the past as a possible new syndrome [9 -11].…”

Section: Discussionmentioning

confidence: 99%

Coexisting hyperparathyroidism, renal osteodystrophy and psoriatic arthritis

Marhoffer

Kaesser

Bauer

et al. 1997

Rheumatology International

View full text Add to dashboard Cite

We report the case of a 60-year-old woman with hyperparathyroidism, renal osteodystrophy and psoriatic arthritis. The coexistence of findings of hyperparathyroidism and renal osteodystrophy has been described and there are also reports of patients suffering from renal arthropathy mimicking hyperparathyroidism. To our knowledge, there is no description to date of a case displaying findings of the co-occurrence of these conditions in a patient. We would like to emphasize that attention should be paid to the possible diagnosis of a coexisting inflammatory rheumatic disease when rheumatological symptoms of recent onset occur in patients with long-standing renal osteodystrophy and/or symptoms mimicking hyperparathyroidism occur in these patients.

show abstract

“…It has a molecular weight of 28,000 D and is capable of inhibiting glucose metabo lism, chemotaxis, chemiluminescence as well as bacterial killing by normal neutrophils. This protein is of potential clinical signifi cance since neutrophils from chronic renal failure patients have been shown to be func tionally impaired [10]. If this substance is sub sequently found to be present in higher con centration in uremic plasma compared to nor mal plasma, it too should be considered as a middle molecule.…”

Section: Isolation Of Specific Middle Moleculesmentioning

confidence: 99%

“…Clearances of sol utes with Mr -10,000-20,000 by most highfiux membranes are at least an order of mag nitude greater than those by most low-flux membranes. Limited clinical studies have shown that dialysis using high flux mem branes is associated with less carpal tunnel syndrome and bone amyloidosis [10,11], less protein catabolism [12], lower serum choles terol and triglyceride levels [13,14], and lower patient mortality [15,16]. In the report of Gotch and Uehlinger [15], patient mortality was far superior than that of the US national average when UKM was carefully monitored despite short treatment time (mean 2.25 h).…”

Section: Effect Of High Flux Membranesmentioning

confidence: 99%

Quantitation of Dialysis

Cheung

1994

Blood Purif

View full text Add to dashboard Cite

Despite the availability of calcitriol and recombinant erythropoietin to replace two major endocrine functions of the kidneys, mortality in chronic hemodialysis patients remains substantially higher than that in the general population. This suggests that most, if not all, patients are underdialyzed. While increasing small solute clearance by dialysis using urea kinetics as a guide improves clinical outcome, ‘adequate’ treatment using current techniques is only an arbitrary definition, since solute removal by dialysis remains far inferior to that of the normal native kidneys. In recent years, significant advances have been made in the structural and functional characterization of toxic uremic solutes that are in the higher molecular size range (‘middle molecules’). Several lines of evidence suggest that, in addition to small solutes, removal of middle molecules is also advantageous. The potential beneficial effects of synthetic high flux hemodialysis membranes are probably attributed to both their solute clearance profiles as well as their biocompatibility characteristics.

show abstract

Carpal tunnel syndrome and type of dialysis membrane used in patients undergoing long‐term hemodialysis

Cited by 21 publications

References 8 publications

Radiolucent Bone Cysts and the Type of Dialysis Membrane Used in Patients Undergoing Long-Term Hemodialysis

Radiolucent Bone Cysts and the Type of Dialysis Membrane Used in Patients Undergoing Long-Term Hemodialysis

Coexisting hyperparathyroidism, renal osteodystrophy and psoriatic arthritis

Quantitation of Dialysis

Contact Info

Product

Resources

About